# Aprea Therapeutics

Source: https://onco.cc/companies/aprea-therapeutics/  
OnCo record `aprea-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Aprea developed eprenetapopt, a drug meant to restore the function of mutant p53, which failed its phase 3 trial in TP53-mutant myelodysplastic syndromes in 2020; the company now works on ATR and WEE1 inhibitors.

## Summary

Aprea Therapeutics, founded in Stockholm and now based in Doylestown, Pennsylvania and listed on Nasdaq, developed eprenetapopt (APR-246), a small molecule intended to refold mutant p53 into its active form. Combined with azacitidine it produced encouraging phase 2 remissions in TP53-mutant myelodysplastic syndromes, but the phase 3 trial missed its complete remission endpoint in December 2020. The company pivoted to DNA damage response drugs, including the ATR inhibitor ATRN-119 and a WEE1 inhibitor. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Aprea Therapeutics, Inc.; Aprea
- Tags: ctgov-sponsor
- HQ: Doylestown, PA
- Type: biotech
- Website: https://aprea.com

## Sources

- Official website: https://aprea.com
- ClinicalTrials.gov: trials led by Aprea Therapeutics: https://clinicaltrials.gov/search?lead=Aprea%20Therapeutics

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [ATR](https://onco.cc/targets/atr/), [TP53](https://onco.cc/targets/tp53/)
- drugs: [Eprenetapopt](https://onco.cc/drugs/eprenetapopt/)

---
JSON: https://onco.cc/api/v1/entities/aprea-therapeutics.json